|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatocellular carcinoma,hepatitis C virus infection and miRNA involvement:Perspectives for new therapeutic approaches显示文摘Chronic hepatitis C virus(HCV)infection is the principal etiology of cirrhosis and,ultimately,hepatocellular carcinoma(HCC).At present,approximately 71 million people are chronically infected with HCV,and 10%–20%of these are expected to develop severe liver complications throughout their lifetime.Scientific evidence has clearly shown the causal association between miRNAs,HCV infection and HCC.Although it is not completely clear whether miRNA dysregulation in HCC is the cause or the consequence of its development,variations in miRNA patterns have been described in different liver diseases,including HCC.Many studies have analyzed the importance of circulating miRNAs and their effect on cell proliferation and apoptosis.In this Review,we aim to summarize current knowledge on the association between miRNA,HCV and HCC from a diagnostic point of view,and also the potential implications for therapeutic approaches. | Ester Badami Rosalia Busà Bruno Douradinha Giovanna Russelli Vitale Miceli Alessia Gallo Giovanni Zito Pier Giulio Conaldi Gioacchin Iannolo | 2022 | World Journal of Gastroenterology2022，28，22： | 2 |
| 2 | Mesenchymal stromal cell secretome in liver failure:Perspectives on COVID-19 infection treatment显示文摘Due to their immunomodulatory potential and release of trophic factors that promote healing,mesenchymal stromal cells(MSCs)are considered important players in tissue homeostasis and regeneration.MSCs have been widely used in clinical trials to treat multiple conditions associated with inflammation and tissue damage.Recent evidence suggests that most of the MSC therapeutic effects are derived from their secretome,including the extracellular vesicles,representing a promising approach in regenerative medicine application to treat organ failure as a result of inflammation/fibrosis.The recent outbreak of respiratory syndrome coronavirus,caused by the newly identified agent severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),has forced scientists worldwide to use all available instruments to fight the infection,including the inflammatory cascade caused by this pandemic disease.The use of MSCs is a valid approach to combat organ inflammation in different compartments.In addition to the lungs,which are considered the main inflammatory target for this virus,other organs are compromised by the infection.In particular,the liver is involved in the inflammatory response to SARS-CoV-2 infection,which causes organ failure,leading to death in coronavirus disease 2019(COVID-19)patients.We herein summarize the current implications derived from the use of MSCs and their soluble derivatives in COVID-19 treatment,and emphasize the potential of MSCbased therapy in this clinical setting. | Cinzia Maria Chinnici Giovanna Russelli Matteo Bulati Vitale Miceli Alessia Gallo Rosalia Busà Rosaria Tinnirello Pier Giulio Conaldi Gioacchin Iannolo | 2021 | World Journal of Gastroenterology2021，27，17： | 1 |
| 3 | Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells:Potential implications for their clinical use显示文摘Mesenchymal stromal/stem cells(MSCs)have shown significant therapeutic potential,and have therefore been extensively investigated in preclinical studies of regenerative medicine.However,while MSCs have been shown to be safe as a cellular treatment,they have usually been therapeutically ineffective in human diseases.In fact,in many clinical trials it has been shown that MSCs have moderate or poor efficacy.This inefficacy appears to be ascribable primarily to the heterogeneity of MSCs.Recently,specific priming strategies have been used to improve the therapeutic properties of MSCs.In this review,we explore the literature on the principal priming approaches used to enhance the preclinical inefficacy of MSCs.We found that different priming strategies have been used to direct the therapeutic effects of MSCs toward specific pathological processes.Particularly,while hypoxic priming can be used primarily for the treatment of acute diseases,inflammatory cytokines can be used mainly to prime MSCs in order to treat chronic immune-related disorders.The shift in approach from regeneration to inflammation implies,in MSCs,a shift in the production of functional factors that stimulate regenerative or anti-inflammatory pathways.The opportunity to fine-tune the therapeutic properties of MSCs through different priming strategies could conceivably pave the way for optimizing their therapeutic potential. | Vitale Miceli Giovanni Zito Matteo Bulati Alessia Gallo Rosalia Busà Gioacchin Iannolo Pier Giulio Conaldi | 2023 | World Journal of Stem Cells2023，15，5： | 1 |
| 4 | Gender-specific characteristics of atherosclerosis in menopausal women:risk factors,clinical course and strategies for prevention显示文摘 | Vitale C Miceli M Rosano GM | 2007 | Climacteric2007，10，： | 1 |
| 5 | Use of priming strategies to advance the clinical application of mesenchymal stromal/stem cell-based therapy显示文摘Mesenchymal stromal/stem cells(MSCs)have garnered significant attention in the field of regenerative medicine due to their remarkable therapeutic potential.MSCs play a pivotal role in maintaining tissue homeostasis and possess diverse functions in tissue repair and recovery in various organs.These cells are charac-terized by easy accessibility,few ethical concerns,and adaptability to in vitro cultures,making them a valuable resource for cell therapy in several clinical conditions.Over the years,it has been shown that the true therapeutic power of MSCs lies not in cell engraftment and replacement but in their ability to produce critical paracrine factors,including cytokines,growth factors,and exosomes(EXOs),which modulate the tissue microenvironment and facilitate repair and regeneration processes.Consequently,MSC-derived products,such as condi-tioned media and EXOs,are now being extensively evaluated for their potential medical applications,offering advantages over the long-term use of whole MSCs.However,the efficacy of MSC-based treatments varies in clinical trials due to both intrinsic differences resulting from the choice of diverse cell sources and non-standardized production methods.To address these concerns and to enhance MSC therapeutic potential,researchers have explored many priming strategies,including exposure to inflammatory molecules,hypoxic conditions,and three-dimensional culture techniques.These approaches have optimized MSC secretion of functional factors,empowering them with enhanced immunomodulatory,angiogenic,and regenerative properties tailored to specific medical conditions.In fact,various priming strategies show promise in the treatment of numerous diseases,from immune-related disorders to acute injuries and cancer.Currently,in order to exploit the full therapeutic potential of MSC therapy,the most important challenge is to optimize the modulation of MSCs to obtain adapted cell therapy for specific clinical disorders.In other words,to unlock the complete potential of MSCs in regenerative medicine,it is crucial to identify the most suitable tissue source and develop in vitro manipulation protocols specific to the type of disease being treated. | Vitale Miceli | 2024 | World Journal of Stem Cells2024，16，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员